Day One Biopharmaceuticals, Inc. 8-K

What Happened
Day One Biopharmaceuticals, Inc. (DAWN) issued a press release on January 11, 2026 (filed on Form 8-K) announcing preliminary, unaudited OJEMDA net product revenue results for Q4 and the year ended December 31, 2025, and reporting cash, cash equivalents and short-term investments as of December 31, 2025. The company cautioned these figures are estimates subject to completion of the year-end close and may change materially. Day One also disclosed its 2026 priorities and will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.

Key Details

• Press release dated January 11, 2026 announced preliminary (unaudited) OJEMDA net product revenue for Q4 and full-year 2025 and reported cash, cash equivalents and short-term investments as of December 31, 2025.
• The preliminary financial metrics are estimates and subject to final closing procedures; actual audited results may differ materially.
• Clinical milestones and timing announced for 2026: complete enrollment in the pivotal Phase 3 FIREFLY-2 trial in H1 2026; initial Phase 1a DAY301 (PTK7 ADC) data in H2 2026; deliver Emi‑Le Phase 1 clinical data by mid‑2026.
• Company is participating in the J.P. Morgan Healthcare Conference (Jan 12, 2026) and provided presentation materials with the 8-K.

Why It Matters
Preliminary revenue and cash figures give investors an early view of the company’s commercial performance and liquidity heading into 2026, but these numbers are unaudited and may change. The announced 2026 clinical milestones (FIREFLY-2 enrollment completion, DAY301 and Emi‑Le data timing) are near-term development catalysts that could affect the company’s clinical progress and valuation if achieved. Investors should note the company’s forward‑looking caution: these projections involve risks and uncertainties and are not guarantees of results.